Physician

Anthony Ming Szema, MD

According to 2025 Medicare claims, Anthony Szema, MD (NPI: 1831159649) practices allergy/immunology in the Nassau County-Suffolk County, NY market, with the plurality of this provider's patient population coming from Suffolk, NY. This provider's primary affiliated billing organization is THREE VILLAGE ALLERGY & ASTHMA, PLLC (NPI: 1568718971; TIN: 455617451) and primary practice location at 11720-1155.

Szema's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 196 traditional Medicare patients, billed 30,675 HCPCS/CPT codes, and received $643,903 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 417 prescription claims across 132 beneficiaries totaling $1,906,949 in drug costs, led by Takhzyro (Lanadelumab-Flyo). DME data shows 198 claims. Open Payments data shows 1 records totaling $40. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $52,458 to $643,903. In contrast, Part D prescription costs have declined steadily, from $3,192,161 to $1,906,949. For DME billing, this smaller-volume category rose steadily, from $146 to $17,095.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	85	2,917	$52,458
2016	129	4,354	$83,745
2017	162	4,852	$88,293
2018	147	4,381	$71,033
2019	145	7,850	$167,661
2020	147	9,473	$261,419
2021	231	17,069	$454,598
2022	195	19,117	$486,537
2023	186	29,953	$609,029
2024	196	30,675	$643,903

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	49	148	$3,192,161
2016	75	272	$3,296,850
2017	90	301	$1,957,980
2018	101	348	$1,908,599
2019	104	385	$2,295,358
2020	102	440	$1,971,398
2021	118	478	$1,693,041
2022	136	574	$1,652,528
2023	129	492	$1,572,039
2024	132	417	$1,906,949

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	77	$49,448
2017	N/R	86	$32,808
2018	N/R	126	$34,332
2019	N/R	63	$33,851
2020	N/R	144	$54,815
2021	N/R	137	$57,222
2022	N/R	156	$83,288
2023	59	381	$108,007
2024	20	198	$126,120

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	78	174	$110
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	128	292	$79
96372	Injection of drug or substance under skin or into muscle	48	517	$12
95004	Test for allergy using allergenic extract	47	2,429	$4
96160	Administration and interpretation of patient-focused health risk assessment	44	66	$3

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Takhzyro	Lanadelumab-Flyo	14	392	$713,525
Fasenra	Benralizumab	20	1,154	$115,424
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	40	3,180	$65,610
Dupixent Syringe	Dupilumab	13	364	$45,423
Xolair	Omalizumab	14	392	$38,154

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1559	Injection, immune globulin (hizentra), 100 mg	N	N/R	22	$108,603
E0483	High frequency chest wall oscillation system, with full anterior and/or posterior thoracic region receiving simultaneous external oscillation, includes all accessories and supplies, each	Y	N/R	15	$12,788
E0791	Parenteral infusion pump, stationary, single or multi-channel	Y	N/R	13	$2,488
J7626	Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mg	N	N/R	15	$769
Q0513	Pharmacy dispensing fee for inhalation drug(s); per 30 days	N	N/R	20	$492

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$40	GlaxoSmithKline, LLC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Anthony Ming Szema, MD?

Tedicare shows public-source Medicare data for Anthony Ming Szema, MD (NPI 1831159649), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Anthony Ming Szema, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Anthony Ming Szema, MD?

Anthony Ming Szema, MD is linked to THREE VILLAGE ALLERGY & ASTHMA, PLLC (billing NPI 1568718971) in the available physician profile data.

Does Anthony Ming Szema, MD have Open Payments data?

Anthony Ming Szema, MD has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.